CompletedPhase 1NCT01344798
Clinical Study of AAV1-gamma-sarcoglycan Gene Therapy for Limb Girdle Muscular Dystrophy Type 2C
Studying Gamma-sarcoglycan-related limb-girdle muscular dystrophy R5
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Genethon
- Principal Investigator
- Serge Herson, ProfAssistance Publique - Hôpitaux de Paris
- Intervention
- AAV1-gamma-sarcoglycan vector injection(biological)
- Enrollment
- 9 enrolled
- Eligibility
- 15 years · All sexes
- Timeline
- 2006 – 2010
Study locations (1)
- Hôpital Pitié-Salpêtrière, Paris, France
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01344798 on ClinicalTrials.govOther trials for Gamma-sarcoglycan-related limb-girdle muscular dystrophy R5
Additional recruiting or active studies for the same condition.
See all trials for Gamma-sarcoglycan-related limb-girdle muscular dystrophy R5 →